Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martha C Nason

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Science Translational Medicine|July 4, 2014
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorAmarendra Pegu, Zhi-yong Yang, Jeffrey C Boyington, et al.
The Journal of Experimental Medicine|August 27, 2014
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaquesMasashi Shingai, Olivia K Donau, Ronald J Plishka, et al.
Nature|August 15, 2014
Enhanced neonatal Fc receptor function improves protection against primate SHIV infectionSung-Youl Ko, Amarendra Pegu, Rebecca S Rudicell, et al.
The Journal of Infectious Diseases|March 14, 2013
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoireJoseph P Casazza, Kathryn A Bowman, Selorm Adzaku, et al.
Science Translational Medicine|October 16, 2015
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human seraJoan O Ngwuta, Man Chen, Kayvon Modjarrad, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Nature Communications|August 12, 2024
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.
Science Translational Medicine|June 12, 2020
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualitySonia Maciejewski, Tracy J Ruckwardt, Kaitlyn M Morabito, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (<i>Macaca fascicularis</i>)Courtney L Finch, Ian Crozier, Ji Hyun Lee, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Science Translational Medicine|July 4, 2014
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorAmarendra Pegu, Zhi-yong Yang, Jeffrey C Boyington, et al.
The Journal of Experimental Medicine|August 27, 2014
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaquesMasashi Shingai, Olivia K Donau, Ronald J Plishka, et al.
Nature|August 15, 2014
Enhanced neonatal Fc receptor function improves protection against primate SHIV infectionSung-Youl Ko, Amarendra Pegu, Rebecca S Rudicell, et al.
The Journal of Infectious Diseases|March 14, 2013
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoireJoseph P Casazza, Kathryn A Bowman, Selorm Adzaku, et al.
Science Translational Medicine|October 16, 2015
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human seraJoan O Ngwuta, Man Chen, Kayvon Modjarrad, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Nature Communications|August 12, 2024
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysMatthew Gagne, Barbara J Flynn, Christopher Cole Honeycutt, et al.
Science Translational Medicine|June 12, 2020
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualitySonia Maciejewski, Tracy J Ruckwardt, Kaitlyn M Morabito, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (<i>Macaca fascicularis</i>)Courtney L Finch, Ian Crozier, Ji Hyun Lee, et al.
Pageof 7